Streptococcus pneumoniae causes serious illnesses like pneumonia and meningitis in children, highlighting the urgent need for new vaccines due to changes in bacterial serotypes among vaccinated groups.
Research has focused on Pneumococcal surface protein A (PspA) as a strong candidate for vaccine development, as it helps the bacteria evade the immune system.
A new method for producing and purifying a specific PspA fragment (PspA4Pro) was developed, resulting in a highly pure product that retains its functional properties, making it a promising component for future vaccine formulations.